- 1 Number of words in the Abstract: 150
- 2 Number of words in the Introduction: 508
- 3 Number of words in the Discussion: 1156
- 4 Number of figures: 1
- 5 Number of tables: 3

6

- 7 Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on
- 8 biomarker and safety outcomes: systematic review, frequentist and Bayesian
- 9 network meta-analyses
- Danko Jeremic, PhD, Juan D. Navarro-López[†], PhD, Lydia Jiménez-Díaz[†], PhD
- †These authors share last senior and corresponding authorship.

12

- NeuroPhysiology & Behavior Lab, Institute of Biomedicine (IB-UCLM), School of
- 14 Medicine of Ciudad Real, 13005, University of Castilla-La Mancha, Spain.

15

- *Correspondence to:
- 17 J.D. Navarro-Lopez and L. Jimenez-Diaz
- 18 Neurophysiology and Behavior Lab
- 19 Universidad Castilla-La Mancha
- 20 13071-Ciudad Real
- 21 Phone: + 34-926295300 ext 6838
- 22 Fax: + 34-926295300
- 23 E-mail: Juan.Navarro@uclm.es; Lydia.Jimenez@uclm.es

- 25 **Keywords**: Network Meta-Analysis; Bayesian; Frequentist; Alzheimer's; Anti-amyloid;
- 26 Aducanumab; Lecanemab; Donanemab;

27 ABSTRACT

28

29

33

INTRODUCTION

- 30 Questions remain regarding safety and clinical relevance of anti-amyloid antibodies in
- 31 Alzheimer's disease (AD), with no scientific basis for choosing between different
- 32 therapies.

METHODS

- 34 Systematic review, frequentist and Bayesian network meta-analyses of phase III
- randomized placebo-controlled trials were performed to comparatively evaluate
- 36 cognitive, functional and biomarker efficacy and safety of anti-amyloid antibodies in
- 37 sporadic AD. Treatments were ranked with P- and SUCRA scores, with rank robustness
- measured by Cohen's *kappa*, and uncertainty in ranking probabilities estimated with
- 39 Shannon's normalized entropy.

40 RESULTS

- Based on data from 16,971 patients (16 studies), we found Donanemab the best-ranked
- 42 antibody on cognitive measures. Lecanemab was the most effective at reducing amyloid
- 43 burden. Caution is needed concerning brain edema and microbleeding, with clinically
- important risks for Donanemab, Aducanumab and Lecanemab.

45 **DISCUSSION**

- 46 Risk/benefit profile of anti-amyloid antibodies remains unfavorable. Patients in
- 47 Donanemab study were stratified by tau load, with greater effects observed in
- low/medium *tau* population.

Highlights

removal.

50

- No single therapy ranked the best among all outcomes.
- Donanemab was the most effective antibody at reducing cognitive decline across
 all primary outcomes, while Lecanemab ranked the highest on amyloid PET
- Consistently greater cognitive, functional and biomarker effects of Donanemab
 were observed in patients with low/medium *tau* load, suggesting more promising
 effects in earlier AD stages.
- All antibodies, except Solanezumab, were significantly less tolerable than
 Placebo.
- The risk of cerebral edema and microbleeding may outweigh the benefits,
 independently of APOE status.

1. BACKGROUND

64	Although known for a little more than a century, Alzheimer's disease (AD) became a
65	real-world problem in the last few decades as the most common form of dementia and
66	significant burden for our societies [1]. Until recently, symptomatic treatments were the
67	only therapies available for AD patients, and that situation remains in the majority of
68	countries in the world. The recent approvals of Aducanumab (Aduhelm®, U.S) and
69	Lecanemab (Leqembi®, U.S and Japan) have initiated the new era in AD therapeutics,
70	as these monoclonal antibodies have shown some potential to modify disease
71	progression by binding to amyloid- β (A β) peptide, toxic peptides thought to be essential
72	in the AD pathophysiology [2]. Both Aducanumab (epitope: 3–7) and Lecanemab
73	(epitope: 1–16) have high selectivity for N-terminus of full-length Aβ found in soluble
74	oligomers and fibrils, however, Lecanemab showed tenfold stronger binding to small
75	and large protofibrils than to fibrils [3, 4].
76	The regulatory approvals of Aduhelm® and Leqembi® were both promising and
76 77	The regulatory approvals of Aduhelm® and Leqembi® were both promising and controversial, and they came after more than a decade of investigating anti-A β vaccines
77	controversial, and they came after more than a decade of investigating anti-A β vaccines
77 78	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab
77 78 79	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since
77 78 79 80	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since they failed to show beneficial effects in clinical trials. Another anti-A β antibody,
77 78 79 80 81	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since they failed to show beneficial effects in clinical trials. Another anti-A β antibody, Donanemab, have gained significant attention recently and it is currently under review
77 78 79 80 81 82	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since they failed to show beneficial effects in clinical trials. Another anti-A β antibody, Donanemab, have gained significant attention recently and it is currently under review for standard approval in the EU and the U.S. Instead of binding the N-terminus of full-
77 78 79 80 81 82 83	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since they failed to show beneficial effects in clinical trials. Another anti-A β antibody, Donanemab, have gained significant attention recently and it is currently under review for standard approval in the EU and the U.S. Instead of binding the N-terminus of full-length A β , Donanemab targets the N-truncated pyroglutamate A β (at position 3), present
77 78 79 80 81 82 83	controversial, and they came after more than a decade of investigating anti-A β vaccines and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab (specific to A β monomers) and Bapineuzumab (non-specific) were discontinued since they failed to show beneficial effects in clinical trials. Another anti-A β antibody, Donanemab, have gained significant attention recently and it is currently under review for standard approval in the EU and the U.S. Instead of binding the N-terminus of full-length A β , Donanemab targets the N-truncated pyroglutamate A β (at position 3), present only in A β plaques. It is reported to rapidly induce plaque removal and reduce cognitive

have to demonstrate clinically meaningful effect in real life [9, 10]. We have previously conducted the systematic review and web application meta-analysis of anti-AB antibodies in phase III randomized placebo-controlled clinical trials (RCTs), showing that Aducanumab and Lecanemab produced the most promising biomarker results (reducing both A β and tau load) and improved cognitive outcomes by small effect size when compared to control group. However, these cognitive effects were achieved at the great expense of increasing adverse events, most importantly amyloid-related imaging abnormalities (ARIA) in the form of cerebral edema (ARIA-E), hemorrhages and localized superficial siderosis (ARIA-H) [11]. Our study had some limitations, as we performed only the conventional (frequentist) meta-analysis method with DerSimonian and Laird random-effect model. This did not allow us to estimate the relative effects and compare the performance of these treatments. Also, we did not analyze amyloid PET data from original studies, and we failed to include the effects of Donanemab, as phase III trial results on this drug were not available at the time. Therefore, our aim in this study was to update and expand our previous study by conducting random-effect frequentist and Bayesian network meta-analyses (NMAs) of phase III RCTs in order to compare the effects of anti-AB antibodies and rank their performance across cognitive, functional, biomarker and safety outcomes.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

2. METHODS

107

108

129

2.1. Search strategy

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses 109 110 (PRISMA) – NMA guideline of health care interventions [12]. The comprehensive search for published phase III trials was done on March 11, 2024, using the following 111 112 keywords: "Alzheimer's", "sporadic", "mild cognitive impairment", "phase 3", "monoclonal antibody", "passive immunotherapy", "Aducanumab", "BIIB037", 113 "Lecanemab", "BAN-2401", "Solanezumab", "LY2062430", "Bapineuzumab" and 114 "AAB-001", "Donanemab" and "LY3002813". The search was performed on Google 115 Scholar, PubMed, and clinical trial databases, including International Clinical Trials 116 117 Registry Platform (ICTRP) of the World Health Organization, the U.S. Clinical trial 118 Registry Clinical Trials.gov, The EU Clinical Trial Registry and Australian New Zealand Clinical Trials Registry (ANZCTR). 119 2.2. Quality assessment 120 Modified Jadad scale was used to assess the methodological quality of clinical trial 121 reports. The Jadad scale, also known as the Oxford quality scoring system has been 122 tested for reliability in different settings [13, 14] and includes the evaluation of study 123 124 randomization, blindness of patients and investigators, blindness in outcome 125 assessment, report of withdrawals, and dropouts [15]. In addition, we evaluated 126 reporting of the methodology used to assess adverse events (most notably ARIA), 127 whether ARIA is reported depending on the APOE genotype, and whether the methods of the statistical analysis were described in the study. The studies were excluded if they 128

(1) had modified Jadad score < 3; (2) were not phase III RCTs; (3) did not include

patients with mild cognitive impairment (MCI) or sporadic AD; (4) tested less than 50 participants for cognitive and safety measures.

2.3. Risk of bias

The potential bias was classified as "low risk", "with some concerns", or "high risk, by using Revised Cochrane risk-of-bias tool (RoB 2). The domains encompassed in RoB 2 analysis cover all types of bias that are currently understood to affect the results of RCTs: (1) bias arising from the randomization process; (2) bias due to deviations from intended interventions; (3) bias due to missing outcome data; (4) bias in measurement of the outcome; and (5) bias in selection of the reported result [16]. Risk-of-bias assessments were visualized using RoB 2 web app [17]. Finally, publication bias was statistically evaluated for efficacy outcomes with more than ten studies [18] by using Egger's regression test [19], funnel plots, and the Duval & Tweedie's Trim-and-Fill procedure [20].

2.4. Grading the evidence and the impact of COVID-19 pandemic

To evaluate the quality of underlying evidence and the strength of recommendations in this study, we followed Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach that focuses on six items: within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence. In addition, the impact of COVID-19 pandemic on each study was evaluated by summarizing the number (%) of patients affected by COVID-19 disease (Drug vs. Placebo) and how the pandemic affected each stage of the trial, including adverse events and dropouts, missing doses, delays and staffing difficulties, and whether the impact of COVID-19 was analyzed in the main and sensitivity analyses.

154	Primary outcomes included efficacy measures reported by all or the majority of the
155	original studies. These were mean changes from baseline in cognitive function
156	evaluated by AD Assessment Scale-Cognitive Subscale (ADAS-Cog), Clinical
157	Dementia Rating scale-Sum of Boxes (CDR-SB), and Mini Mental State Examination
158	(MMSE).
159	Secondary outcomes were biomarker and safety measures reported by all or the majority
160	of studies. Biomarker outcomes included changes from baseline in amyloid burden on
161	PET (centiloid scale), cerebrospinal fluid (CSF) levels of $A\beta_{1-42}$ and p-tau (Thr ₁₈₁), and
162	plasma <i>p-tau</i> . Safety measures were Serious adverse events, tolerability (treatment
163	discontinuations due to adverse events), total events of ARIA-E (cerebral edema),
164	cerebral microhemorrhages, total events of ARIA-H (including cerebral
165	microhemorrhages, macrohemorrhages and superficial siderosis), headaches, fatigue,
166	dizziness, syncope, nausea, falls, cardiac disorders, back pain, arthralgia,
167	nasopharyngitis, upper respiratory and urinary infections.
168	Tertiary outcomes included efficacy and safety measures reported by few studies only:
169	functional scale AD Cooperative Study-Activities of Daily Living in MCI (ADCS-
170	ADL-MCI), superficial siderosis (ARIA-H), infusion-related reactions and total events
171	of ARIA-E and ARIA-H in APOE-ε4 non-carriers and carriers (total and depending on
172	the ε4 allele dose).
173	The results of NMAs were summarized by League Tables with Standardized Mean
174	Differences (SMDs) calculated for efficacy (continuous) outcomes, and Relative Risks
175	(natural logarithm) for safety outcomes.

2.6. Data analysis and reporting

The aims of this study were to: (1) update our previous study by performing conventional (frequentist) random-effect meta-analysis with DerSimonian and Laird method and (2) conduct frequentist and Bayesian NMA to assess comparative efficacy and safety of anti-amyloid antibodies. The results obtained from different methods were then compared for each outcome. In order to properly manage the differences among multiple subgroups within the primary studies with respect to differences in drug doses, biomarker findings and other patient characteristics, we followed the recommendation to treat each subgroup as a separate study [21].

2.6.1. Frequentist NMA

Frequentist random-effects NMA was conducted using the *netmeta* package [22] in R (version 4.2.2). The values of I² statistic and their statistical significance were evaluated for overall heterogeneity or inconsistency in the network, which was then split into within-design (i.e., heterogeneity) and between-design (i.e., inconsistency) and the statistical significance of Q-values was assessed. For each outcome, the results are presented in the form of league tables and treatment rankings calculated as P-scores by using *netrank* function from *netmeta* package [22-24]. P-score of 1 is the best possible score and 0 is the worst. Further information on this ranking can be found in the Method section of the Supplement.

2.6.2. Bayesian NMA

Bayesian random-effect NMA was performed by using *rjags* and *gemtc* packages in R

[25] and JAGS 4.3.0 software [26] that allow automating NMA in the Bayesian

hierarchical model framework with uninformative priors and Markov chain Monte

Carlo (MCMC) estimation. The number of tuning iterations was set at 10 and the

number of simulation iterations at 100,000. Convergence of the MCMC model was assessed through Gelman-Rubin plots and the potential scale reduction factor. Trace and density plots were then applied to determine the best parameters of the number of burnin iterations, the number actual simulation iterations, and thinning parameter. For each outcome, the results are presented in the form of league tables and rankings are calculated in the form of SUCRA score (surface under the cumulative ranking curve). This score can be interpreted as the estimated proportion of treatments worse than the treatment of interest (0% \leq SUCRA \leq 100%). Values of SUCRA close to 1 (100%) indicate the higher likelihood that specific treatment is the best. To calculate the SUCRA scores in R, we used the *sucra* function from *dmetar* package in R [23]. Further information on SUCRA score can be found in the Supplement.

2.6.3. Influence and Sensitivity Analyses

Influence analyses were done to detect outliers and influential studies in the network.

These included heterogeneity assessments using Baujat plots, Influence diagnostics, and Leave-One-Out meta-analysis. Then, graphic display of study heterogeneity (GOSH) plot analysis was used to examine the results of an equal-effects model in the combinatorial meta-analyses with all possible subsets of studies [23, 27]. GOSH plot diagnostics employs three unsupervised machine learning algorithms: (1) k-means clustering based on vector quantization [28], (2) density-based spatial clustering of applications with noise (DBSCAN) [29], and (3) probabilistic Gaussian mixture model (GMM) [30]. Sensitivity analyses were then performed by rerunning frequentist and Bayesian NMAs upon excluding influential observations.

2.6.4. Rank Robustness

To quantify the influence a study had on the SUCRA based treatment ranks, the

robustness of ranks was evaluated within the sensitivity analyses, upon excluding all influential studies and during Leave-One-Out meta-analysis. The influence of study elimination on the ranks in the Bayesian NMA was estimated by using quadratic weighted Cohen's kappa [31], as recently proposed by Daly and colleagues [32]. This allowed us to measure the agreement between the ranks produced with the complete dataset and the ranks produced from sub-datasets generated upon removing influential studies and each study at a time. The magnitude of Cohen's kappa is usually categorised into levels of agreement for interpretation (eg, poor (<0%), slight (0%-20%), fair (21%40%), moderate (41%–60%), substantial (61%–80%) and almost perfect (81%– 100%) agreement). However, it should be added that a kappa is not an index of accuracy but of agreement beyond chance [33], and that the uncertainty of rankings and other study characteristics that are context-dependent should be incorporated into the interpretation of the results, as a kappa value of 90%, for example, is not always indicative of almost perfect rank agreement [32]. The calculations were performed by using cohen.kappa function available in psych package in R [34]. In addition, the robustness of each rank was examined by determining how many (%) studies did not change any treatment rank (%), as well as how many (%) studies displaced treatment ranks.

2.6.5. Rank Uncertainty

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

The uncertainty of the SUCRA ranks in Bayesian NMA is visualized by rankograms and tables that show the distribution of the ranking probabilities [35-37], as suggested by the PRISMA–NMA guideline and GRADE working group. Furthermore, we measured Shannon's information entropy, as recommended recently by Wu et al (2021) [38]. The authors suggested very intuitive way to estimate uncertainty associated with ranking probabilities in NMA by applying Shannon's information entropy formula to obtain a

normalised entropy score. Their work showed that the normalised entropy score gives a more accurate assessment of ranking uncertainty and does not depend on the number of analysed treatments. This approach can be used to compare the uncertainty of treatment rankings within a NMA and also between different NMAs, which is crucial for interpretation of results [38].

For a NMA, the most precise scenario would be that we are absolutely certain in the ranking of treatments in our network. Therefore, each treatment would have 100% probability of being in one ranking position and 0% probability for the other positions (peaked distribution). Under this scenario, the entropy is zero bit, and Shannon's normalized entropy equals zero. On the other hand, the normalized entropy reaches 1 in the least precise scenario when the ranking probabilities are the same for each rank (flat distribution). In this work, we regarded as "low" those values of normalized entropy that were equal or lower than 0.25 and "moderate" those between 0.25 and 0.5. Larger values were considered as conveying "high" or "substantial" uncertainty or normalized entropy associated with ranking probabilities. Further information on normalized entropy score, and the code for calculation are located in the Supplement.

2.6.6. Clinical relevance

Finally, the clinical relevance of the statistically significant results (compared to Placebo) from the frequentist main NMA and sensitivity analyses was assessed by calculating the "Number Needed to Treat" (NNT) or "Number Needed to Harm" (NNH) from the treatment's pooled effect size (Hedges g') by Area Under the Curve (AUC) method [39]. Here, AUC is defined as the probability that a patient receiving the treatment has an outcome preferable to one receiving Placebo. Lower NNT and higher NNH values are associated with a more favorable benefit/risk profile. The best NNT is 1, indicating that for every patient treated one got better, while NNT > 1, means that the

fewer people will benefit the treatment [23]. Similarly, NNH of 1 means that for every patient treated one got harmed, while NNH > 1 suggests that fewer people will be harmed.

2. RESULTS

274

275

276

277

The results obtained from the conventional (frequentist) meta-analysis with 278 279 DerSimonian-Laird estimator were very similar to the Frequentist and Bayesian NMA results. Due to word limitation and large consistency in the findings, this manuscript 280 281 will only refer to the results obtained from the NMAs. Conventional meta-analysis will be reproducible online in AlzMeta.app (https://alzmetaapp.shinyapps.io/alzmeta/), upon 282 publication of this work. 283 284 The meta-analysis included 16 studies (11 ClinicalTrials.gov registries), considering different subgroups within certain RCTs as separate studies, according to our 285 286 methodology [21]. Bapineuzumab was tested in six studies [40, 41], Solanezumab in 287 three studies [42, 43] Aducanumab in four studies ([44]), Donanemab in two studies (low/medium-tau and high-tau populations from TRAILBLAZER-ALZ 2 [8], and 288 289 Lecanemab in one study [45]. The details concerning the quality of reports from 290 primary studies (modified Jadad scale) can be found in the Supplement (Supplementary Tables A1 and A2), as well as the number of records identified, included and excluded, 291 292 and the overall reasons for exclusions (PRISMA Flow Diagram, Supplement), along 293 with PRISMA Checklist (Supplement). Specific reasons for excluding each primary study are listed in Supplementary Tables A3 and A4 (Supplement). 294 In total, 16,971 patients were analyzed in the primary studies, 8,447 (mean age 71,43) 295 296 years) received Placebo, while 8,524 (mean age 71,87) were passively immunized 297 against A\u00e3. All treatments lasted either 76 or 78 weeks across multiple centers, with the

average number of trial sites 212.27 (median 198). Acetylcholinesterase inhibitors and memantine were allowed during the trials, alone or in combination. Additional baseline participant characteristics and the inclusion criteria for primary studies are documented in the Supplement (Table A5 and A6). Statistical power was 100% assuming moderate between-studies heterogeneity and any possible effect size (small, medium, large) (Fig. S1, Supplement). Regarding risk of bias, all studies were considered as either "low risk" or raising "some concerns" (Fig. S2a,b and Table A7; Supplement). For each outcome, certainty of evidence is rated low or very low within each comparison, according to GRADE approach (Table A8; Supplement), with low number of studies being the most important reason for downgrading the certainty.

2.1. Primary outcomes

Frequentist NMA results showed that Donanemab, Lecanemab and Aducanumab were significantly more effective than Placebo on ADAS-Cog (cognitive scale, Table 1A). Bapineuzumab and Solanezumab had no favorable effects, with frequentist (but not Bayesian) NMA results suggesting that Placebo was superior to Solanezumab on this scale. In frequentist framework, Donanemab was significantly more effective than Bapineuzumab and Solanezumab and had a double effect size compared to that achieved with Aducanumab and Lecanemab. Bayesian NMA results revealed strong evidence that Aducanumab and Donanemab improved ADAS-Cog and the lack of convincing support for the effects of Lecanemab. Furthermore, in Bayesian framework, we found strong indication that Donanemab outperformed Bapineuzumab, but not Solanezumab, which was clear from the credible intervals including zero (Table 1B).

Even better results were obtained on cognitive and functional (global) scale CDR-SB (Table 1C), where Donanemab, Lecanemab and Aducanumab were significantly more effective than Placebo. Donanemab was more effective than other interventions with nearly three times greater effect size than that of the approved antibodies. Aducanumab and Lecanemab were significantly more effective than Bapineuzumab, however, with the confidence intervals very close to zero. Bayesian NMA produced very similar results as frequentist NMA on CDR-SB, with the exception of three indirect comparisons (Donanemab vs. Lecanemab; Lecanemab vs Bapineuzumab and Aducanumab vs Bapineuzumab), where credible intervals included zero, suggesting the lack of strong evidence for the non-zero effect in these comparisons (Table 1D). Frequentist NMA results for MMSE (cognitive) score revealed weaker effects of all drugs in the network, with Donanemab and Solanezumab significantly more effective than Placebo (MMSE results for Lecanemab were not reported). These results were fully validated by Bayesian NMA (Table S1; Supplement). Heterogeneity was not significant for any primary outcome, and inconsistency was not assessed because the network did not have a closed loop. We found no evidence of publication bias, with the Egger's test p-values 0.661, 0.8462, and 0.8929 for ADAS-Cog, CDR-SB, and MMSE, respectively. Funnel plots were symmetric for all three outcomes (Fig. S3a-c in the Supplement), and the imputation of potentially "missing studies" did not change results. Across all primary outcomes, Donanemab was the best-ranked antibody according to both frequentist P-scores [24] and SUCRA scores [35] in Bayesian framework. On CDR-SB, Donanemab obtained the maximum scores (near 1) and very low Shannon's normalized (information) entropy score [38]. This suggests high certainty in the ranking probabilities for Donanemab on CDR-SB. In contrast, on ADAS-Cog and MMSE,

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

SUCRA scores for Donanemab were 0.93 and 0.89 respectively, with moderate uncertainty in the ranking probabilities (Fig. 1C and Table P1 in the Supplement). Donanemab produced clinically the most relevant effects on all primary outcomes in combined low/medium population and high-tau population, with NNT = 9 on ADAS-Cog, 6 on CDR-SB and 13 on MMSE. When Donanemab was compared to Aducanumab and Lecanemab, the most striking difference was observed on CDR-SB, with NNT values almost two times higher for Lecanemab (13) and almost three times higher for Aducanumab (18). On ADAS-Cog, Lecanemab and Aducanumab also had high NNT (15). Finally, Solanezumab had high NNT (20) on MMSE, suggesting low clinical relevance of cognitive effects of this drug.

2.2. Secondary outcomes

2.2.1. Biomarkers of Aβ and tau

Both Frequentist and Bayesian NMA results showed that Lecanemab, Donanemab, and Aducanumab significantly improved clearance of Aß deposits from brain when compared to Placebo (Table S2.1; Supplement). Lecanemab demonstrated the greatest amyloid-clearance activity on PET and obtained P- and SUCRA scores very close to 1, with high certainty (low information entropy) associated with the ranking probabilities (Table P1 in the Supplement). However, despite large effect-sizes, these data should be interpreted with caution, as substantial heterogeneity was found between the studies and the number of analyzed trials/patients was small. While frequentist NMA results indicated significant differences between Lecanemab and other antibodies, Bayesian NMA results revealed a lack of strong evidence that Lecanemab outperformed Aducanumab and Donanemab on this outcome.

Frequentist NMA results revealed that Aducanumab and Lecanemab were significantly 369 370 superior to Placebo on CSF biomarkers of Aβ₁₋₄₂ and p-181-tau (data for Donanemab were not reported). Aducanumab significantly outperformed Solanezumab on CSF Aβ 371 (Table S2.1) and Bapineuzumab on CSF p-tau (Table S2.2.). Bayesian NMA validated 372 the relative effect of Aducanumab on both CSF Aβ and p-tau, providing strong evidence 373 in favor of positive effects of Aducanumab on these outcomes when compared to 374 375 Placebo, but not when compared to other drugs. Furthermore, Bayesian NMA results revealed an absence of strong evidence that Lecanemab was superior to Placebo on CSF 376 Aβ and p-tau. Aducanumab was ranked the best treatment on both CSF biomarkers of 377 378 Aβ and p-tau, with SUCRA scores 0.86 and 0.89, respectively, and moderate uncertainty in the ranking probabilities (Table P1; Supplement). 379 As in case with amyloid PET data, these findings should be interpreted carefully, since 380 CSF biomarker analyses were available only for limited number of patients in few 381 studies, and considerable heterogeneity was found for CSF A β (I² = 68.9% [20.0%; 382 87.9%]; p-value of Q statistics = 0.012), indicating that the true effect size may vary 383 384 across studies. Heterogeneity was not significant for CSF p-tau (Table S2.2; Supplement), while the analysis of plasma tau biomarkers had to be dropped because of 385 extreme heterogeneity ($I^2 = 99\%$ [98.5%; 99.3%], p < 0.0001) and differences in 386 measured biomarker outcome. 387 All biomarker effects were clinically relevant for Aducanumab, Lecanemab and 388 Donanemab, with NNT values of 1 for the effects on amyloid burden (PET data), 389 indicating that the favorable effect on amyloid removal was accomplished for each 390 391 treated patient, with each of these antibodies. NNTs for CSF outcomes were also very small (clinically relevant) for Aducanumab and Lecanemab, with NNT = 2 on CSF $A\beta_{1-}$ 392 42 for both antibodies. As for CSF-p-tau, the NNT of Aducanumab (3) was somewhat 393

lower than that of Lecanemab (4), reflecting slightly greater effect of Aducanumab on ptau.

2.2.2. Safety outcomes

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

Anti-amyloid antibodies did not increase the risk of serious adverse events (Table S3.1; Supplement). Nevertheless, both the frequentist and Bayesian NMA results provide substantial evidence that high-clearance antibodies (Donanemab, Lecanemab and Aducanumab) were less tolerable than Placebo and Solanezumab since these drugs greatly increased the risk of treatment discontinuation due to adverse events (Table 2). Donanemab was the least tolerable antibody in the network, significantly worse than Bapineuzumab and Aducanumab. Frequentist NMA results revealed considerable risks of discontinuation for Bapineuzumab when compared to Placebo, however, this was not corroborated in Bayesian analysis. Frequentist and Bayesian NMA results provide compelling evidence that Solanezumab was the most tolerable and the safest antibody in terms of ARIAs (Fig. 1C, Table 2). Other antibodies substantially increased the total risk of ARIA-E and the risk of cerebral microhemorrhages (ARIA-H), when compared to Placebo and Solanezumab. Furthermore, Aducanumab, Donanemab and Lecanemab significantly increased the total risk of ARIA-H (including all the events of cerebral superficial siderosis, micro- and macrohemorrhages), when compared to Solanezumab and Placebo (Tables S3.2 and S3.3 in the Supplement) Frequentist NMA on additional safety outcomes showed that Aducanumab significantly increased the risk of headaches (Table S3.4) and falls (Table S3.5; Supplement) when compared to Placebo, however, with confidence intervals very close to zero and substantial heterogeneity between the studies (see 3.6). Further Bayesian NMA revealed

lack of conclusive support for these comparisons. Similarly, in Bayesian framework, 418 419 there was an absence of strong evidence that Donanemab increased the risk of nausea in high-tau population, when compared to Placebo, whereas frequentist NMA would 420 suggest significant difference in risk (Table S3.6; Supplement). 421 Further analyses showed that anti-Aβ did not raise the risks of fatigue, dizziness, 422 arthralgia, back pain, cardiac disorders, diarrhea, nor urinary infections more than 423 424 Placebo (Table S3.7-S3.16; Supplement). In addition, we found no improved risk of 425 syncope, nasopharyngitis and upper respiratory infections, however, these events were not reported for Donanemab and Lecanemab, antibodies tested in clinical trials affected 426 427 by COVID-19 pandemic (see 2.4 section). Heterogeneity was not significant for secondary safety outcomes with the exception of risks of headaches and cardiac 428 disorders. 429 430 The risks of treatment discontinuation due to adverse events, total ARIA-E, cerebral 431 microhemorrhages, and total ARIA-H were all clinically relevant, with NNH values of 432 1, which correspond to the situation in which for each patient treated, one exhibited treatment-emergent adverse reaction. 433 434 2.3. Tertiary outcomes Frequentist NMA of ADCS-MCI-ADL showed that Aducanumab (NNT = 12) and 435 Lecanemab (NNT = 10) significantly slowed functional decline by small effect size, 436 437 when compared to Placebo. Bayesian NMA results validated these results for 438 Aducanumab, but not for Lecanemab (Table S4.1). The heterogeneity was not significant; however, these results should be interpreted with care since they are based 439 on four studies with Aducanumab and one study testing Lecanemab. Furthermore, 440

credible intervals for the relative effects of Aducanumab (vs. Placebo) were very close 441 442 to zero, indicating uncertainty in the evidence (also, see 2.4). 443 Both frequentist and Bayesian NMA results gave strong support for increased risk of 444 superficial siderosis (ARIA-H) in patients treated with Donanemab and Aducanumab, when compared to those in control group, while the results for Lecanemab were not 445 conclusive. Whereas frequentist NMA results suggested significantly greater risk (p = 446 447 0.001) of superficial siderosis in patients treated with Lecanemab (compared to Placebo), Bayesian NMA gave an estimate with overlapping credible intervals, 448 suggesting the lack of strong evidence for this comparison (Table S4.2). Even so, the 449 450 risk of superficial siderosis was clinically relevant for Donanemab, Aducanumab and Lecanemab, with NNH values of 1 (the least favorable). 451 452 The risk of infusion-related reactions was clinically meaningful (NNH = 1) for 453 Donanemab and Lecanemab (not reported for other drugs), significantly higher (p < 454 0.0001) when compared to Placebo. Both the Frequentist and Bayesian NMA results 455 provided strong evidence that Donanemab increased the risks of infusion-related reactions, with almost two times greater risk than that observed in Lecanemab study 456 (Table S4.3 in the Supplement). 457 Having in mind the limited information regarding ARIA-E and ARIA-H depending on 458 the APOE status, frequentist and Bayesian NMAs strongly indicate that all antibodies, 459 460 except Solanezumab, significantly increased the risk of ARIA-E in both APOE-E4 carriers and non-carriers. The results were not that convincing for ARIA-H, where 461 462 smaller risks were observed and frequentist NMA results suggested significant increase in risk for Donanemab and Lecanemab in both carriers and non-carriers, which was not 463 validated in Bayesian framework. Due to inconclusive findings on ARIAs depending on 464 APOE status, we were unable to determine whether the risk of ARIAs increases 465

substantially with $\epsilon 4$ allele dose (homozygotes vs. heterozygotes). Overall, the risk of ARIAs was clinically relevant (NNH = 1) independently of APOE status, and the risk generally increased with each $\epsilon 4$ allele (Tables S4.4-S4.7 in the Supplement). Heterogeneity between the studies could not be assessed due to small numbers of studies.

2.4. Sensitivity analyses

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Donanemab consistently showed greater cognitive effects in patients with low/medium tau load than in high-tau population (assessed by PET imaging), and removing this study had a big impact on the results, similarly to the greater effect observed for highdose Aducanumab in controversial EMERGE study, as found in our previous metaanalysis [46] (Tables S5 and S7 in the Supplement). For this reason, removing these two studies from the NMAs yielded much lower relative effects of these drugs on cognitive measures (when compared to Placebo), with p-values of 0.0502 and 0.5334 on ADAS-Cog and 0.1419 and 0.0249 on CDR-SB for Aducanumab and Donanemab, respectively. Likewise, excluding study in low/medium-tau population greatly reduced relative effects of Donanemab on MMSE (p = 0.3430), further emphasizing favorable effects of this drug in patients with low/medium tau, but not high tau burden. Bayesian NMA validated these findings, strongly indicating that CDR-SB score was improved by Donanemab (even in high tau population), but not by Aducanumab, after excluding controversial EMERGE study. There was lack of strong evidence for improving both ADAS-Cog and MMSE scores neither by Aducanumab nor by Donanemab after removing their influential studies. Furthermore, frequentist NMA results of amyloid PET data revealed that both Donanemab and Aducanumab significantly removed amyloid brain burden (Table S7.4), when compared to Placebo. Conversely, the results from Bayesian NMA provided strong evidence supporting the efficacy of Aducanumab,

but not Donanemab. In other words, comparatively higher effect of Donanemab was 491 492 obtained in low/medium-tau population, and removing this measurement increased the uncertainty of the evidence, shifting the credible intervals for the relative efficacy of 493 494 Donanemab from (-6.4251; -2.0495) towards (-9.3948; 1.7020). Finally, frequentist NMA results of ADCS-ADL-MCI showed that removing high-dose Aducanumab 495 EMERGE trial did not impact the relative effect of this drug when compared to Placebo 496 497 (Table S7.7). Bayesian NMA weakly favored Aducanumab over Placebo, however, with credible intervals (-0.014; 0.245) including zero. In summary, significant dose-498 499 dependent efficacy of Aducanumab was evident only in EMERGE study, and the 500 relative effects of Donanemab in the main study were largely due to its beneficial effects 501 on AD patients with low/medium *tau* load. Removing the influential studies of Donanemab and Aducanumab reduced ranking 502 scores of these drugs in the network (Figure 1F). On MMSE score, for example, 503 504 Solanezumab was the best-ranked drug with SUCRA score 0.81, followed by 505 Donanemab in high-tau population (0.71). Lecanemab obtained the best score (0.79) on 506 ADAS-Cog, followed by Aducanumab (0.69), and Solanezumab (0.58). Donanemab in high-tau population was the best-ranked treatment only on CDR-SB score (0.91) and 507 508 fourth-ranked on ADAS-Cog (0.3). Additionally, Lecanemab was better ranked treatment than Aducanumab on CSF-Aβ₁₋₄₂ and ADCS-ADL-MCI, upon excluding the 509 510 influential effects from high-dose Aducanumab in EMERGE study. For efficacy outcomes, the most robust SUCRA scores were obtained for CDR-SB, with 92% of 511 512 agreement with the main analysis (median of observed weighted Cohen's kappa values) 513 and 8 (50%) studies that did not change any treatment rank. The robustness of SUCRA scores further improved upon excluding influential Aducanumab and Donanemab 514 studies, however, the uncertainty in ranking probabilities also increased. The least 515

robust SUCRA scores were found for amyloid burden on PET, which was a direct 516 517 consequence of small number of studies. Across all efficacy outcomes, the treatments 518 moved only one or very rarely two ranks up or down upon excluding each study at a time. Further details on ranking probabilities and their sensitivity analysis can be found 519 in the Supplement (Tables P1-P4; Supplement). 520 Clinical relevance of the cognitive and functional effects of Donanemab and 521 522 Aducanumab decreased remarkably upon removing their influential studies. while the 523 biomarker effects on Aβ and *p-tau* remained clinically relevant with small NNTs. For Donanemab, the NNT was 28 for ADAS-Cog and 18 for MMSE, while NNT for CDR-524 525 SB did not change drastically (NNT = 8), when compared to the main analysis (NNT = 6). In other words, the beneficial effects of Donanemab on cognitive and functional 526 CDR-SB score in patients with high-tau load were still clinically relevant, even if the 527 effects were greater in those with low/medium tau. Aducanumab had higher (less 528 529 favorable) NNTs in sensitivity analysis for ADAS-Cog (21) and CDR-SB (19). 530 The results of sensitivity analyses on safety outcomes were largely consistent with the main analysis. SUCRA scores for treatment discontinuation, risks of ARIA-E and 531 ARIA-H were robust to study exclusions, with median weighted Cohen's kappa values 532 533 above 89%, indicating almost perfect agreement in study ranks between main and 534 sensitivity analysis (Tables P1-P4 in the Supplement). Additionally, there was small statistically significant increase in the risk of headaches for all high-clearance 535 536 antibodies: Aducanumab (p = 0.0001), Donanemab (p = 0.0085), and Lecanemab (p = 0.0085) 0.0323), when compared to Placebo (Table S2.9), after excluding two low-dose 537 538 Bapineuzumab studies [41]. These two studies were the source of high heterogeneity in the main analysis, which was detected by Q statistics (p < 0.0001) and Gaussian 539 Mixture Model in GOSH plot analysis (Table S8.1 and Figure S11 in the Supplement). 540

Bayesian NMA validated frequentist NMA results for Aducanumab and Donanemab, suggesting that these antibodies slightly increased the risk of headaches when compared to Placebo and Solanezumab. On the other hand, there was no conclusive evidence that Lecanemab elevated risk of headaches, when compared to Placebo. Additionally, the statistical significance for the risk of falls in Aducanumab studies dropped (p = 0.8785) once we removed ENGAGE studies (Table S8.2 in the Supplement), suggesting that these studies contributed to the observed high risk of falls in the main analysis.

2.5. The Impact of COVID-19 pandemic

Lecanemab and Donanemab RCTs included in this study were affected by global outbreak of coronavirus – an infectious disease caused by the severe acute respiratory syndrome. COVID-19 was the most commonly reported adverse event across treatment groups in Donanemab studies, ocurring in ~17% of patients in all arms. The impact of pandemic was less severe on Lecanemab study, with the incidence of COVID-19 around 7% in experimental and control groups. The pandemic also caused delays in study visits and assessments in both trials and other difficulties summarized in the Supplement (Table S6).

3. DISCUSSION

558

559

562

563

564

565

566

567

568

569

572

575

576

580

581

582

This study reveals a complex pattern of evidence supporting the efficacy of 560 Aducanumab, Lecanemab and Donanemab across multiple cognitive, functional and 561 biomarker outcomes. At the same time, the risks of cerebral edema and microbleeding were substantial, suggesting greater harm than benefit. The similarities and the differences between frequentist and Bayesian NMA results presented here strongly emphasize the need for further studies with larger sample sizes and the need to study these antibodies in earlier stages of AD and MCI, and in younger patients with lower AB and tau load. The inconsistencies between ENGAGE and EMERGE trials revealed here and in our previous study [46] have been discussed in literature ever since these studies were published, as they caused a lot of controversy within the FDA and in the broader community [47]. The Aducanumab provider, in partial collaboration with the FDA, 570 provided two possible explanations for these discrepancies: (1) fewer numbers of 571 patients in the ENGAGE trial receiving higher doses of drug, and (2) ENGAGE trials 573 had more outliers, and removing these outliers in sensitivity analysis gave more 574 compatible dose-dependent beneficial effects [48, 49]. Despite these inconsistencies, Aducanumab received accelerated approval in the U.S. Afterwards, the FDA granted breakthrough status to Lecanemab and Donanemab, in order to speed up their approval [50], which finally resulted in full FDA approval of Lecanemab in the U.S. and more 577 578 recently in Japan. Furthermore, Lecanemab is currently undergoing regulatory review in 579 the European Union (EU), United Kingdom, South Korea, and Canada, while Donanemab is reviewed in the EU and the U.S [7]. Recent exploratory post hoc modeling based on phase III RCT of Donanemab suggested that Aβ levels in immunized patients would remain below the positivity threshold for almost 4 years without the

treatment. The authors also revealed that greater plaque removal by Donanemab was 583 584 associated with slower progression of tau PET and slower clinical decline, but only in APOE-ε4 carriers [51]. In our study, all high-clearance antibodies (Aducanumab, 585 Donanemab and Lecanemab) produced substantial Aβ and *tau* biomarker effects. 586 587 Donanemab was the best-ranked treatment across all cognitive measures, while Lecanemab was the most efficient at reducing amyloid burden on PET. Donanemab 588 589 consistently showed better cognitive, functional and biomarker effects in patients with low/medium tau load, compared to those with high tau. Donanemab produced clinically 590 591 relevant cognitive effects in low/medium-tau population on all three primary outcomes, 592 suggesting greater benefit of Donanemab in earlier AD stages. Low tolerance and high risk of ARIAs looms over high-clearance anti-Aβ antibodies. 593 Our results showed that Donanemab was significantly less safe and less tolerable than 594 595 Placebo and Solanezumab, with similar risks of treatment discontinuation and ARIAs as 596 in Aducanumab and Lecanemab studies. Both frequentist and Bayesian NMA results 597 from this study imply that the risk of ARIAs associated with the treatment may 598 outweigh the benefits, independently of APOE status. In summary, our results demonstrate modest cognitive and substantial biomarker effects of Donanemab, 599 600 Lecanemab and Aducanumab, yet with significant trade-off in the form of dose-601 dependent cerebral vasogenic edema (ARIA-E), bleeding and hemosiderin deposits 602 (ARIA-H), which may or may not be symptomatic or serious adverse event. These risks require careful dose titration and close patient monitoring on Magnetic Resonance 603 604 Imaging (MRI), which increases the costs of already expensive treatments [52]. In our 605 view, additional and comparative studies of these drugs with vascular biomarkers are 606 needed to evaluate their risk/benefit profile, as well as more anticipatory policies from regulatory bodies if we were to avoid new controversies as those seen with the FDA 607

approval of Aducanumab. Moreover, personalized approach and safer multi-target 608 609 therapies in combination with novel biomarkers is expected to effectively mitigate the 610 AD progression [53]. 611 Different mechanisms of actions of these drugs outlined in the Introduction certainly contribute to the differences in their effects and heterogeneity in our networks. 612 However, there is no doubt that Aducanumab, Lecanemab and Donanemab achieved 613 614 great biomarker results and modest cognitive effects in 18 months. Therefore, comparative and longitudinal studies are required to fully disclose the impact of anti-AB 615 immunotherapy over longer periods of time. Future trials would need to compare the 616 617 effects of anti-Aβ antibodies in multiple stages of AD and in different populations, as inter-individual differences and comorbidities may be crucial to prevent ARIAs and 618 select patients that could benefit from anti-Aß immunotherapy. The inflammation and 619 620 vascular comorbidities are of special concern, as blood-brain barrier disruption and AB 621 deposition are central to the development of both AD (with Aβ deposited in brain 622 parenchyma) and cerebral amyloid angiopathy (with Aβ deposition on blood vessel 623 walls). These two pathologies often co-occur and APOE-ε4 status is known to worsen both of them. Risk factors for ARIA are dose-dependent and include receiving anti-Aβ 624 625 immunotherapy, anticoagulant and thrombolytic medication, carrying APOE-e4 allele, 626 and history of brain microhemorrhages and stroke [54, 55]. The important limitations of this study are (1) COVID-19 impacted Donanemab and 627 628 Lecanemab trials, (2) the patients in Donanemab study were stratified by their level of the brain protein tau; (3) the effects of antibodies on plasma tau biomarkers could not be 629 630 evaluated due to excessive between-study heterogeneity and different measures used in primary studies; (4) potential bias might be introduced due to unmasking, since ARIAs 631 were the most frequent treatment-emergent adverse events of all drugs except 632

Solanezumab, and (5) direct comparison between the antibodies has not been done yet, and our NMA only included studies where treatments were compared with Placebo.

NMA is a statistical method to compare more than two interventions simultaneously by combining direct and indirect evidence. When head-to-head trials are not available, as often happens in many research fields, indirect comparisons can be made via a common control arm (Placebo in our case) [56]. Therefore, this study should be viewed as a way to summarize the results from previous phase III RCTs and provide comparative assessment of these drugs based on existing data, until further evidence comes along. The same should be emphasized for the efficacy and safety rankings and their uncertainty measures, as clinical decision making should never be based solely on one or two measures or studies.

4. RESEARCH IN CONTEXT

- 1. Systematic review and meta-analysis: Frequentist and Bayesian network meta-analyses (NMAs) were performed to compare the efficacy and safety of anti-amyloid antibodies in phase III randomized placebo-controlled trials in sporadic AD.
 - 2. Interpretation: Aducanumab, Lecanemab and Donanemab achieved substantial biomarker results and small cognitive effects, and were less tolerable than Placebo and Solanezumab, significantly increasing the risk of ARIAs.
 Donanemab was the most efficient antibody on the cognitive measures, but it was also the least tolerable, significantly less tolerable than Placebo, Solanezumab, Bapineuzumab and Aducanumab.
 - 3. Future directions: Studying these drugs in earlier stages and in younger patients with lower A β and *tau* burden might yield better outcome than that observed in

phase III trials. Since ARIAs are the major adverse events limiting the broad use
of anti-amyloid antibodies, prevention of vascular damage, better biomarkers and
safer, personalized treatment options are needed to improve AD treatment.

663	ACKNOWLEDGEMENTS
664	This work was supported by grants PID2020-115823-GB100 funded by
665	MCIN/AEI/10.13039/501100011033, and SBPLY/21/180501/000150 funded by
666	JCCM/ERDF - A way of making Europe, and 2022-GRIN-34354 grant by
667	UCLM/ERDF intramural funding to LJ-D and JDN-L.
668	AUTHORS' CONTRIBUTIONS
669	JDNL and LJD were responsible for the initial conceptualization, funding acquisition,
670	supervision, and project administration; DJ was responsible for Data curation, Software,
671	Formal analysis, visualization and writing the original draft; SD, JDNL and LJD did the
672	writing – review and editing. All authors read and approved the final manuscript.
673	CONFLICT OF INTEREST STATEMENT
674	All authors declare that they have no conflicts of interest. The protocol for this study
675	was not previously registered. Author disclosures are available in the Supporting
676	Information.
677	
678	REFERENCES
679	
680 681 682	[1] Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1. [2] Wessels AM, Dennehy EB, Dowsett SA, Dickson SP, Hendrix SB. Meaningful Clinical
683	Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the
684 685	Donanemab TRAILBLAZER-ALZ Study Findings. Neurol Clin Pract. 2023;13:e200127. [3] Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al.
686	Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of
687	Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's
688	Disease. Neurotherapeutics. 2023;20:195-206.
689 600	[4] Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in
690 691	Alzheimer's disease. Neurobiol Dis. 2020;144:105010. [5] Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies:
692	current status and outlook for the future. Alzheimers Res Ther. 2013;5:56.

- [6] Rabinovici GD, La Joie R. Amyloid-Targeting Monoclonal Antibodies for Alzheimer
- 694 Disease. Jama. 2023;330:507-9.
- 695 [7] Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal
- Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2024;38:5-22.
- [8] Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early
- 698 Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
- 699 Jama. 2023;330:512-27.
- 700 [9] Digma LA, Winer JR, Greicius MD. Substantial Doubt Remains about the Efficacy of
- 701 Anti-Amyloid Antibodies. J Alzheimers Dis. 2024;97:567-72.
- 702 [10] Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, et al. Safety and
- 703 Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and
- 704 Meta-Analysis of Published and Unpublished Clinical Trials. J Alzheimers Dis.
- 705 2022;87:101-29.
- 706 [11] Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and safety of anti-amyloid-β
- 707 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic
- review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012.
- 709 [12] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The
- 710 PRISMA extension statement for reporting of systematic reviews incorporating network
- meta-analyses of health care interventions: checklist and explanations. Ann Intern Med.
- 712 2015;162:777-84.
- 713 [13] Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the
- 714 quality of randomized trials: reliability of the Jadad scale. Control Clin Trials.
- 715 1999;20:448-52.
- 716 [14] Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess
- 717 the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88:156-
- 718 75.
- 719 [15] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.
- 720 Assessing the quality of reports of randomized clinical trials: is blinding necessary?
- 721 Control Clin Trials. 1996;17:1-12.
- 722 [16] Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a
- 723 randomized trial. Cochrane handbook for systematic reviews of interventions. 2019:205-
- 724 28
- 725 [17] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
- revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
- 727 [18] Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations
- 728 for examining and interpreting funnel plot asymmetry in meta-analyses of randomised
- 729 controlled trials. Bmj. 2011;343:d4002.
- 730 [19] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by
- 731 a simple, graphical test. Bmj. 1997;315:629-34.
- 732 [20] Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and
- 733 adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-63.
- 734 [21] Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis:
- 735 John Wiley & Sons; 2021.
- 736 [22] Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O,
- et al. netmeta: An R package for network meta-analysis using frequentist methods.
- 738 Journal of Statistical Software. 2023;106:1-40.

- 739 [23] Harrer M, Cuijpers P, Furukawa T, Ebert D. Doing meta-analysis with R: A hands-on
- 740 guide: Chapman and Hall/CRC; 2021.
- 741 [24] Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis
- works without resampling methods. BMC Med Res Methodol. 2015;15:58.
- 743 [25] van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating
- network meta-analysis. Res Synth Methods. 2012;3:285-99.
- 745 [26] Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs
- 746 sampling. Proceedings of the 3rd international workshop on distributed statistical
- 747 computing: Vienna, Austria; 2003. p. 1-10.
- 748 [27] Olkin I, Dahabreh IJ, Trikalinos TA. GOSH a graphical display of study heterogeneity.
- 749 Res Synth Methods. 2012;3:214-23.
- 750 [28] Hartigan JA, Wong MA. Algorithm AS 136: A k-means clustering algorithm. Journal
- of the royal statistical society series c (applied statistics). 1979;28:100-8.
- 752 [29] Schubert E, Sander J, Ester M, Kriegel HP, Xu X. DBSCAN revisited, revisited: why and
- how you should (still) use DBSCAN. ACM Transactions on Database Systems (TODS).
- 754 2017;42:1-21.
- 755 [30] Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density
- estimation. Journal of the American statistical Association. 2002;97:611-31.
- 757 [31] Cohen J. Weighted kappa: nominal scale agreement with provision for scaled
- 758 disagreement or partial credit. Psychol Bull. 1968;70:213-20.
- 759 [32] Daly CH, Neupane B, Beyene J, Thabane L, Straus SE, Hamid JS. Empirical evaluation
- of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using
- 761 Cohen's kappa. BMJ Open. 2019;9:e024625.
- 762 [33] Foody GM. Explaining the unsuitability of the kappa coefficient in the assessment
- and comparison of the accuracy of thematic maps obtained by image classification.
- Remote sensing of environment. 2020;239:111630.
- 765 [34] Revelle W. An introduction to the psych package: Part I: data entry and data
- description. Northwestern University. 2019.
- 767 [35] Salanti G. Indirect and mixed-treatment comparison, network, or multiple-
- 768 treatments meta-analysis: many names, many benefits, many concerns for the next
- 769 generation evidence synthesis tool. Research synthesis methods. 2012;3:80-97.
- 770 [36] Cipriani G, Ulivi M, Danti S, Lucetti C, Nuti A. Sexual disinhibition and dementia.
- 771 Psychogeriatrics. 2016;16:145-53.
- 772 [37] Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative
- 773 efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments
- 774 meta-analysis. Lancet. 2011;378:1306-15.
- 775 [38] Wu Y-C, Shih M-C, Tu Y-K. Using normalized entropy to measure uncertainty of
- rankings for network meta-analyses. Medical Decision Making. 2021;41:706-13.
- 777 [39] Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical
- research and practice. Biol Psychiatry. 2006;59:990-6.
- 779 [40] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3
- 780 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med.
- 781 2014;370:322-33.
- 782 [41] Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al.
- 783 Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized,
- 784 phase 3 trials. Alzheimers Res Ther. 2016;8:18.

- 785 [42] Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of
- 786 solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
- 787 [43] Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of
- 788 Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med.
- 789 2018;378:321-30.
- 790 [44] Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two
- 791 Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev
- 792 Alzheimers Dis. 2022;9:197-210.
- 793 [45] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in
- 794 Early Alzheimer's Disease. N Engl J Med. 2023;388:9-21.
- 795 [46] Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and Safety of Anti-Amyloid-β
- 796 Monoclonal Antibodies in Current Alzheimer's Disease Phase III Clinical Trials: A
- 797 Systematic Review and Interactive Web App-based Meta-Analysis. Ageing Research
- 798 Reviews. 2023:102012.
- 799 [47] Largent EA, Peterson A, Karlawish J, Lynch HF. Aspiring to Reasonableness in
- 800 Accelerated Approval: Anticipating and Avoiding the Next Aducanumab. Drugs Aging.
- 801 2022;39:389-400.
- 802 [48] Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB.
- Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review. Int J Alzheimers
- 804 Dis. 2022;2022:9343514.
- 805 [49] Kuller LH, Lopez OL. ENGAGE and EMERGE: Truth and consequences? Alzheimers
- 806 Dement. 2021;17:692-5.
- 807 [50] Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data
- and controversies. Drugs Context. 2021;10.
- 809 [51] Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al.
- 810 Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and
- 811 Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol.
- 812 2022;79:1015-24.
- 813 [52] Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and
- 814 Donanemab for Early Alzheimer Disease in the US. JAMA Neurol. 2022;79:478-87.
- [53] Toups K, Hathaway A, Gordon D, Chung H, Raji C, Boyd A, et al. Precision Medicine
- 816 Approach to Alzheimer's Disease: Successful Pilot Project. J Alzheimers Dis.
- 817 2022;88:1411-21.
- [54] Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Jr., Poussaint TY, et al.
- 819 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics:
- Detection and Reporting Recommendations for Clinical Practice. AJNR Am J Neuroradiol.
- 821 2022;43:E19-e35.
- 822 [55] Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging
- abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784.
- 824 [56] Higgins JP. Cochrane handbook for systematic reviews of interventions version 6.2.
- 825 Cochrane Database Syst Rev. 2021.




Figure 1. The results of Bayesian NMA for efficacy and safety of anti-amyloid antibodies in Alzheimer's disease in phase III randomized placebo-controlled clinical trials. **A**, **B** and **C** correspond to the main analysis with all studies included, and **D**, **E**

and F refer to the sensitivity analysis with two influential studies left out: Donanemab 833 study in low/medium-tau population and high-dose EMERGE study of Aducanumab. A, 834 **D.** Network models with nodes (circles) representing antibodies, and the width of the 835 edges or links (k) indicating the number of studies included for each comparison. B, E. 836 Rankogram for global (cognitive and functional) outcome CDR-SB. The Y axis 837 represents the probability for each treatment being the best option, second best option, 838 third best option etc. (legend). C, F Scatterplots showing jointly the ranking results for 839 efficacy and safety of drugs in the network. SUCRA scores were calculated for the main 840 efficacy outcomes (X-axes: CDR-SB and ADAS-Cog) and safety measures (Y-axes: 841 tolerability and risk of any ARIA-E). Abbreviations: ARIA-E, Amyloid-Related 842 Imaging Abnormalities in form of cerebral Edema; CDR-SB, Clinical Dementia Rating 843 Sum of Boxes; SUCRA, Surface Under Cumulative RAnking curve. 844

848 Table 1. League tables representing the results of random-effect model Frequentist and Bayesian network meta-analysis (NMA). The values in the tables represent 849 850 Standardized Mean Differences (SMDs) for cognitive outcome Alzheimer's Disease Assessment Scale-Cognitive sub-scale (ADAS-Cog, A, B) and for global (cognitive and 851 functional) outcome Clinical Dementia Rating Sum of Boxes (CDR-SB, C, D). The 852 number below 0 suggests that the drug in the column is superior to the drug in the row. 853 Darker green colors correspond to relatively greater effects, and bolded numbers denote 854 statistical significance (A, C) or strong evidence (B, D). The numbers in parentheses 855 represent confidence intervals (CIs) in Frequentist NMA (A, C) or credible intervals 856 (CrIs) in Bayesian framework (**B**, **D**). Dagger symbol (†) denotes that the interpretation 857 differs considerably between frequentist and Bayesian NMA results, indicating the 858 uncertainty and lack of strong evidence for a non-zero effect. 859

860

Table 1A. Frequentist Network Meta-Analysis: ADAS-Cog

	•		•	O	
Aducanuma b					
-0.0960 (-0.1949; 0.003)	Bapineuzu mab				
0.0913 (-0.0444; 0.227)	0.1873 (0.0624; 0.3121)	Donanemab			
-0.0017 (-0.1251; 0.1217)	0.0943 (-0.0171; 0.2057)	-0.0930 (-0.238; 0.052)	Lecanemab		
-0.1174 * (-0.1968; - 0.038)	-0.0214 (-0.0805; 0.0376)	-0.2087 ** (-0.3187; - 0.0987)	-0.1157 † *** (-0.2101; - 0.0213)	Placebo	
-0.0503 (-0.1502; 0.0497)	0.0457 (-0.039; 0.1304)	-0.1416 † (-0.2672; - 0.0159)	-0.0486 (-0.1609; 0.0637)	0.0671 † **** (0.0064; 0.1278)	Solanezu mab

Statistical significance for Drug vs. Placebo: * p = 0.0038; ** p = 0.0002; *** p = 0.0163; **** p = 0.0303

Heterogeneity $I^2 = 0\%$ [0.0%; 58.3%]; p-value of Q statistics = 0.6985 in heterogeneity (within designs).

Table 1B. Bayesian Network Meta-Analysis: ADAS-Cog

Aducanuma b		
-0.0959	Bapineuzu mab	

(-0.2065; 0.0178)					
0.0853 (-0.068; 0.2344)	0.1803 (0.0386; 0.3196)	Donanemab			
-0.0025 (-0.1519; 0.1465)	0.0932 (-0.0461; 0.2342)	-0.0870 (-0.2589; 0.0872)	Lecanemab		
-0.1176 (-0.2058; - 0.0288)	-0.0218 (-0.0890; 0.0446)	-0.2026 (-0.3246; - 0.0778)	-0.1154 † (-0.2371; 0.0060)	Placebo	
-0.04958 (-0.16684; 0.0646)	0.0454 (-0.0569; 0.1468)	-0.1358 † (-0.2784; 0.0108)	-0.0479 (-0.1905; 0.0947)	0.0676 † (-0.0092; 0.1421)	Solanezu mab

Table 1C. Frequentist Network Meta-Analysis: CDR-SB

Aducanuma b					
-0.1053 † (-0.2073; - 0.0033)	Bapineuzu mab				
0.2046 (0.0622; 0.3471)	0.3099 (0.1791; 0.4407)	Donanemab			
0.0357 (-0.0977; 0.1690)	0.1409 † (0.0202; 0.2617)	-0.1690 † (-0.3255; - 0.0125)	Lecanemab		
-0.1004 * (-0.1829; - 0.0180)	0.0048 (-0.0552; 0.0649)	-0.3051 ** (-0.4213; - 0.1889)	-0.1361 *** (-0.2409; - 0.0313)	Placebo	
-0.0473 (-0.1547; 0.0602)	0.0580 (-0.0334; 0.1494)	-0.2519 (-0.3870; - 0.1168)	-0.0829 (-0.2083; 0.0425)	0.0532 (-0.0157; 0.1220)	Solanezu mab

Statistical significance: Drug vs. Placebo * p = 0.017; ** p < 0.0001; *** p = 0.0109

Heterogeneity $I^2 = 9.8\%$ [0.0%; 48.8%] p-value of Q statistics = 0.3493 in heterogeneity (within designs).

Table 1D. Bayesian Network Meta-Analysis: CDR-SB

Aducanuma b			
-0.1045 † (-0.2215, 0.0142)	Bapineuzu mab		
0.2022 (0.0361, 0.3628)	0.3063 (0.1493, 0.4552)	Donanemab	
0.0351 (-0.1328, 0.2049)	0.1397 † (-0.0191, 0.2954)	-0.1672 † (-0.3579, 0.033)	Lecanemab

-0.101	0.0037	-0.3026	-0.1358		
(-0.1961, -	(-0.0683,	(-0.4359, -	(-0.2771,	Placebo	
0.0073)	0.0736)	0.1642)	0.0032)		
-0.0499	0.0547	-0.2522	-0.0849	0.0511	Solanezu
(-0.1814,	(-0.0615,	(-0.4118, -	(-0.2558,	(-0.0387,	
0.0762)	0.164)	0.0918)	0.0779)	0.1372)	mab

Table 2. League tables representing the results of random-effect model Frequentist 864 NMA and Bayesian NMA. The values in the tables represent Relative Risks (natural 865 logarithm) for tolerability (treatment discontinuations due to adverse events, A, B) and 866 for amyloid-related imaging abnormalities in form of cerebral edema (ARIA-E, C, D). 867 For each comparison, the number below 0 suggests that the drug in the column is safer 868 than the drug in the row. Darker red colors correspond to relatively higher risk. Bolded 869 numbers indicate statistical significance for Frequentist NMA (A, C), or strong evidence 870 in Bayesian NMA (**B**, **D**). The numbers in parentheses represent confidence intervals 871 (CIs) for Frequentist NMA (A, C), or credible intervals (CrIs) in Bayesian framework 872 (B, D). Dagger symbol (†) denotes when the interpretation differs significantly between 873 frequentist and Bayesian NMA results, indicating the uncertainty and lack of strong 874 evidence for a non-zero risk. 875

876

877

Table 2A. Frequentist Network Meta-Analysis: Tolerability (Treatment Discontinuations due to Adverse Events)

Aducanuma b					
0.2939 (-0.0956; 0.6835)	Bapineuzu mab				
-0.6066 (-1.0984; - 0.1148)	-0.9007 (-1.3042; - 0.4969)	Donanema b			
-0.1013 (-0.6663; 0.4639)	-0.3951 (-0.8855; 0.095)	0.5054 (-0.0695; 1.0802)	Lecanema b		
0.4973 * (0.1576; 0.837)	0.2033 † ** (0.0126; 0.3941)	1.1039 *** (0.7483; 1.4596)	0.5985 **** (0.1469; 1.0501)	Placebo	
0.4879 (0.0683; 0.9075)	0.194 (-0.1175; 0.5055)	1.0945 (0.6619; 1.5272)	0.5891 (0.0747; 1.1036)	-0.0093 (-0.2557; 0.237)	Solanezu mab

Statistical significance: Drug vs. Placebo: * p = 0.0041; ** p = 0.0367; *** p < 0.0001; **** p = 0.0094

Heterogeneity $I^2 = 0\%$ [0.0%; 58.3%]; p-value of Q statistics = 0.9681 in heterogeneity (within designs).

Table 2B. Bayesian Network Meta-Analysis: Tolerability (Treatment Discontinuations due to Adverse Events)

Aducanuma b	
0.3021	Bapineuzu mab

(-0.1091, 0.7240) -0.6015 (-1.1231, - 0.0708)	-0.9037 (-1.3593, - 0.4631)	Donanema b			
-0.0962 (-0.7213, 0.5193)	-0.4024 (-0.9524, 0.1380)	0.5020 (-0.1335, 1.1416)	Lecanemab		
0.4985 (0.1378, 0.8585)	0.1973 † (-0.0195, 0.4092)	1.1006 (0.7128, 1.5001)	0.5993 (0.0926, 1.1026)	Placebo	
0.4882 (0.0415, 0.9542)	0.1879 (-0.1697, 0.5445)	1.0923 (0.6117, 1.5767)	0.5932 (0.0163, 1.1629)	-0.0093 (-0.2870, 0.2734)	Solanezu mab

Table 2C. Frequentist Network Meta-Analysis: Total events of cerebral edema (ARIA-E)

Aducanuma					
b					
-0.1948	Bapineuzu				
(-0.862;	mab				
0.4723)	mao				
-0.0471	0.1477	Donanema			
(-0.7302;	(-0.6694;	h			
0.6361)	0.9648)	U			
0.4015	0.5963	0.4486			
(-0.3838;	(-0.3077;	(-0.4674;	Lecanemab		
1.1866)	1.5004)	1.3646)			
2.4197 *	2.6145 *	2.4668 *	2.0182 *		
(2.0703;	(2.0462;	(1.8797;	(1.3151;	Placebo	
2.7691)	3.1828)	3.0539)	2.7213)		
2.5416	2.7365	2.5887	2.1402	0.122	Solanezu
(1.7171;	(1.798;	(1.6388;	(1.1145;	(-0.6249;	mab
3.3662)	3.6749)	3.5387)	3.1659)	0.8688)	шао

Statistical significance for Drug vs. Placebo: * p < 0.0001.

Heterogeneity $I^2 = 25.6\%$ [0.0%; 63.1%]; p-value of Q statistics = 0.1997 in heterogeneity (within designs).

Table 2D. Bayesian Network Meta-Analysis: Total events of cerebral edema (ARIA-E)

Aducanuma b		
-0.2148 (-1.1414, 0.5154)	Bapineuzu mab	
-0.0492	0.1619	Donanema b

(-0.9452, 0.8161)	(-0.7384, 1.2530)				
0.4018 (-0.6774, 1.4623)	0.6111 (-0.4272, 1.9019)	0.4492 (-0.7444, 1.6828)	Lecanemab		
2.4186 (1.9414, 2.8973)	2.6376 (2.0373, 3.3955)	2.4691 (1.7415, 3.2262)	2.0176 (1.0681, 2.9953)	Placebo	
2.5342 (1.4692, 3.4767)	2.7477 (1.6868, 3.8665)	2.5816 (1.3860, 3.6877)	2.1355 (0.7887, 3.3623)	0.1090 (-0.8196, 0.9406)	Solanezu mab

